EcoDrugPlus

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSMZEG00005012488
Gene Symbol: PSMA1
3 Cross references
270 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSMZEG00005006983
Gene Symbol: PSMA2
3 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSMZEG00005017210
Gene Symbol: PSMA3
3 Cross references
238 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSMZEG00005013732
Gene Symbol: PSMA4
4 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSMZEG00005000324
Gene Symbol: PSMA5
3 Cross references
210 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSMZEG00005025374
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSMZEG00005011140
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSMZEG00005026338
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSMZEG00005012437
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSMZEG00005019106
Gene Symbol: PSMB4
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSMZEG00005023960
Gene Symbol: PSMB8
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSMZEG00005006179
Gene Symbol: PSMC1
3 Cross references
281 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).